Analyst Sara Nik from H.C. Wainwright reiterated a Buy rating on Cantargia AB and keeping the price target at SEK14.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sara Nik has given his Buy rating due to a combination of factors related to Cantargia’s clinical and financial positioning. She views the growing activity and clarity in the pancreatic ductal adenocarcinoma, or PDAC, arena as supportive for Cantargia, since the company’s core strategy is to move its lead asset, nadunolimab, into a pivotal Phase 2b/3 trial in first-line PDAC during the second half of 2026.
In addition, she emphasizes the company’s expanding autoimmune and oncology pipeline, particularly the IL1RAP-directed bispecific antibody CAN14, for which a second target is expected to be revealed by year-end 2026. The solid year-end cash balance, which management believes funds operations into early 2027, underpins Cantargia’s ability to advance these programs, leading her to maintain a constructive long-term outlook and a Buy recommendation on the shares.